AIM ImmunoTech Inc. (AIM): Price and Financial Metrics
AIM Price/Volume Stats
| Current price | $0.20 | 52-week high | $0.62 |
| Prev. close | $0.18 | 52-week low | $0.16 |
| Day low | $0.18 | Volume | 1,017,600 |
| Day high | $0.20 | Avg. volume | 290,226 |
| 50-day MA | $0.26 | Dividend yield | N/A |
| 200-day MA | $0.36 | Market Cap | 12.74M |
AIM Stock Price Chart Interactive Chart >
AIM ImmunoTech Inc. (AIM) Company Bio
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
AIM Price Returns
| 1-mo | -25.65% |
| 3-mo | -45.89% |
| 6-mo | -48.05% |
| 1-year | -52.94% |
| 3-year | -85.07% |
| 5-year | -51.92% |
| YTD | -54.54% |
| 2023 | 41.04% |
| 2022 | -66.10% |
| 2021 | -48.60% |
| 2020 | 229.04% |
| 2019 | -93.17% |
Loading social stream, please wait...